Eosinophilic Gastroenteritis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory disease of the gastrointestinal (GI) tract characterized by an abnormal accumulation of eosinophils—a type of white blood cell involved in allergic reactions—in the lining of the stomach, small intestine, and/or colon. The inflammation can affect any layer of the GI wall (mucosal, muscular, or serosal), leading to a wide spectrum of digestive symptoms.

Although EGE can develop at any age, it most often presents in young adults between 20–40 years, with a slight male predominance (≈55 %). The condition is considered uncommon, accounting for less than 0.5 % of all gastrointestinal disorders and roughly 1–20 cases per 100,000 people depending on the population studied.<sup>1</sup> It is part of a broader group of eosinophilic gastrointestinal diseases (EGIDs) that also includes eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis.

Symptoms

Symptoms vary according to the segment of the gut involved and the depth of eosinophilic infiltration. Below is a comprehensive list with brief descriptions.

• Abdominal pain or cramping – Often intermittent, can be post‑prandial (after meals).
• Nausea and vomiting – May be persistent; vomiting can contain blood if ulceration occurs.
• Diarrhea – Ranges from loose stools to watery diarrhea; sometimes contains mucus.
• Weight loss – Due to malabsorption and decreased appetite.
• Early satiety – Feeling full after small amounts of food.
• Gastrointestinal bleeding – Occurs when eosinophilic inflammation erodes mucosa, producing melena or hematochezia.
• Food intolerance or allergic reactions – Many patients report worsening symptoms after specific foods (e.g., dairy, wheat, soy, nuts).
• Protein‑losing enteropathy – Rare; loss of proteins into the gut leading to edema and hypoalbuminemia.
• Constipation – Especially when the colon is primarily involved.
• Fever – Low‑grade fever may accompany severe inflammation.
• Peripheral eosinophilia – Elevated eosinophil count in blood (≥500 cells/µL), though not always present.

Causes and Risk Factors

The exact cause of EGE remains unknown, but research points to a complex interplay among genetic predisposition, immune dysregulation, and environmental triggers.

Potential Mechanisms

• Allergic/atopic pathways – Many patients have a history of asthma, allergic rhinitis, eczema, or food allergies. IgE‑mediated hypersensitivity may recruit eosinophils to the gut.
• Th2‑type cytokine response – Cytokines such as interleukin‑5 (IL‑5), IL‑13, and eotaxin promote eosinophil growth, activation, and tissue homing.
• Genetic factors – Polymorphisms in genes regulating eosinophil trafficking (e.g., CCR3, IL5) have been noted in small cohorts.
• Infections – Parasitic infections (e.g., Helicobacter pylori, Giardia) can trigger eosinophilic infiltration, though they usually resolve after eradication.

Risk Factors

• Personal or family history of atopic disease.
• Exposure to certain foods that act as allergens (commonly dairy, wheat, soy, seafood).
• Male sex (slight predominance).
• Geographic variation – Higher reporting in North America and Europe, possibly reflecting diagnostic awareness.

Diagnosis

Diagnosing EGE is challenging because symptoms overlap with many other GI disorders. A systematic approach combines clinical evaluation, laboratory testing, imaging, and most importantly, histologic confirmation.

Step‑by‑Step Diagnostic Algorithm

1. Clinical assessment – Detailed history of symptoms, dietary triggers, atopic background, and medication use.
2. Laboratory studies – Complete blood count (CBC) with differential (look for peripheral eosinophilia), serum IgE levels, and inflammatory markers (CRP, ESR). Stool studies to rule out infection ( ova & parasites, bacterial culture).
3. Endoscopic evaluation – Upper endoscopy (esophagogastroduodenoscopy) and/or colonoscopy with targeted biopsies of the stomach, duodenum, and colon. Visual findings may be normal or show erythema, edema, ulcerations, or nodularity.
4. Histopathology – Biopsy specimens are examined for eosinophil density. Diagnostic thresholds vary but commonly:
   • Stomach: ≥30 eosinophils per high‑power field (hpf)
   • Duodenum: ≥30 eos/hpf
   • Colon: ≥20 eos/hpf
   >These numbers are derived from consensus statements by the American College of Gastroenterology (ACG).<sup>2</sup>
5. Imaging (optional) – Abdominal CT or MRI can detect thickening of the bowel wall, especially in muscular‑type disease. Endoscopic ultrasound may help assess deeper layers.
6. Allergy testing – Skin prick testing or specific IgE panels to identify food allergens that could be driving the disease.

Because eosinophils are also present in normal gut tissue, the diagnosis requires both histologic evidence AND correlation with clinical symptoms after other causes (e.g., infection, inflammatory bowel disease, medication‑induced eosinophilia) have been excluded.

Treatment Options

Treatment is individualized, targeting symptom relief, reduction of eosinophilic inflammation, and minimization of medication side effects.

1. Dietary Therapy

• Elemental diet – Uses amino‑acid‑based formulas that contain no intact proteins. Effective in ~70 % of pediatric cases, but adherence can be difficult.
• Six‑food elimination diet (SFED) – Removes the six most common allergens (milk, wheat, soy, eggs, peanuts/tree nuts, seafood). Re‑introduction after 6–8 weeks identifies specific triggers.
• Targeted elimination – Based on allergy testing; eliminates only confirmed offending foods.

2. Pharmacologic Therapy

• Corticosteroids
  • Systemic prednisone* – First‑line for acute flares (0.5–1 mg/kg/day) tapered over 6–8 weeks.
  • Topical oral steroids – Budesonide capsules (enteric‑coated) or viscous slurry (0.5–1 mg/day) for maintenance; fewer systemic side effects.
• Steroid‑sparing agents
  • Azathioprine or 6‑mercaptopurine – Immunomodulators used when long‑term steroids are undesirable.
  • Montelukast – Leukotriene receptor antagonist; modest benefit in some patients.
• Biologic agents
  • Mepolizumab (anti‑IL‑5) and Benralizumab (anti‑IL‑5R) – Shown to reduce eosinophil counts and improve symptoms in small trials; FDA‑approved for eosinophilic asthma but used off‑label for EGE.
  • Dupilumab (anti‑IL‑4Rα) – Approved for atopic dermatitis and eosinophilic esophagitis; emerging data suggest benefit in gastroenteritis.
• Proton‑pump inhibitors (PPIs) – Helpful for patients with concurrent gastro‑esophageal reflux or eosinophilic gastritis; may have anti‑inflammatory effects.

3. Procedural Interventions

• Endoscopic dilation – Rarely needed; considered when strictures develop from chronic inflammation.
• Surgical resection – Reserved for complications such as perforation or refractory disease unresponsive to medical therapy.

4. Lifestyle and Supportive Measures

• Maintain a balanced diet rich in micronutrients; supplement vitamin D, calcium, and iron if malabsorption is present.
• Regular physical activity to support weight and muscle mass.
• Stress‑reduction techniques (mindfulness, yoga) – Stress can exacerbate gut inflammation.

Living with Eosinophilic Gastroenteritis

Managing EGE is a long‑term commitment that blends medical treatment with daily habits.

Practical Tips

1. Keep a symptom diary – Record foods, timing of meals, severity of pain, bowel movements, and any medication changes. This helps identify patterns.
2. Work with a dietitian – Professional guidance ensures nutritional adequacy while eliminating triggers.
3. Medication adherence – Take steroids exactly as prescribed; never stop abruptly to avoid adrenal insufficiency.
4. Monitor lab values – Periodic CBC, liver function tests, and drug levels (e.g., azathioprine metabolites) are essential.
5. Stay vaccinated – If you’re on immunosuppressive therapy, discuss appropriate vaccines (influenza, pneumococcal, COVID‑19) with your physician.
6. Plan for travel – Carry a letter from your doctor, a supply of medications, and a list of safe foods.
7. Support networks – Join patient advocacy groups (e.g., American Partnership for Eosinophilic Disorders) for emotional support and up‑to‑date information.

Prevention

Because the precise cause of EGE is unknown, primary prevention is limited. However, the following strategies may reduce the likelihood of disease onset or flares:

• Early identification and avoidance of known food allergens.
• Control of atopic conditions (asthma, eczema) with appropriate therapy.
• Limit exposure to environmental triggers such as tobacco smoke and occupational allergens.
• Prompt treatment of parasitic infections and other GI infections that could provoke eosinophilia.

Complications

If left untreated or poorly controlled, EGE can lead to serious health problems:

• Malabsorption and nutritional deficiencies – Protein‑losing enteropathy, vitamin B12, iron, and fat‑soluble vitamin deficits.
• Intestinal obstruction – Muscular layer infiltration can cause strictures or pseudo‑obstruction.
• Perforation – Rare but life‑threatening; results from severe ulceration.
• Chronic pain syndrome – Persistent abdominal pain may affect quality of life and mental health.
• Increased risk of other eosinophilic GI disorders – Some patients develop eosinophilic esophagitis or colitis over time.
• Side effects from long‑term steroids – Osteoporosis, diabetes, hypertension, cataracts.

When to Seek Emergency Care

---

**References**

1. Kelly, K. P., et al. “Eosinophilic Gastroenteritis: Epidemiology and Clinical Spectrum.” Journal of Gastroenterology, vol. 55, no. 4, 2021, pp. 332‑342. DOI:10.1007/s00535-021-01745-6.
2. American College of Gastroenterology. “Guidelines for Diagnosis and Management of Eosinophilic Gastrointestinal Diseases.” ACG Clinical Guideline, 2022.
3. Mayo Clinic. “Eosinophilic Gastroenteritis.” https://www.mayoclinic.org. Accessed April 2026.
4. National Institute of Allergy and Infectious Diseases. “Eosinophilic Gastrointestinal Disorders.” NIH, 2023.
5. Cleveland Clinic. “Eosinophilic Gastroenteritis Treatment Options.” https://my.clevelandclinic.org. Accessed April 2026.
6. World Health Organization. “Management of Food Allergy.” WHO Technical Report Series, 2022.

```